Rani Therapeutics Holdings, Inc. Class A ( (RANI) ) has released its Q4 earnings. Here is a breakdown of the information Rani Therapeutics Holdings, Inc. Class A presented to its investors.
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on developing technologies for the oral delivery of biologics and drugs, utilizing its proprietary RaniPill® capsule platform to potentially replace subcutaneous injections or intravenous infusions.
Rani Therapeutics has reported its financial results for the fourth quarter and full year 2024, alongside significant corporate updates. The company highlighted its preclinical successes in demonstrating the bioequivalence of its oral delivery platform for obesity treatments, notably with the RaniPill® capsule, which showed promising results in delivering GLP-1/GLP-2 dual agonists and semaglutide.
Key financial metrics from the report include a net loss of $15.7 million for the fourth quarter and $56.6 million for the full year 2024, a decrease from the previous year. The company also completed two equity offerings, raising approximately $20 million, and reported cash and marketable securities totaling $27.6 million as of December 31, 2024. Rani’s strategic partnership with ProGen Co., Ltd. for the co-development of an oral obesity treatment was also a notable highlight.
Rani Therapeutics is optimistic about the future, with plans to initiate a Phase 1 clinical trial for RT-114, an oral obesity treatment, in mid-2025. The company believes its RaniPill® platform has the potential to revolutionize the oral delivery of biologics, offering more convenient and accessible therapeutic options.